2 news items
BioAge Appoints Renowned Cardiologist and Biopharma Entrepreneur Michael H. Davidson, MD, to its Board of Directors
NAMS
9 Apr 24
immense potential to amplify the weight loss benefits of incretins, and critically, to prevent the deleterious consequences of significant weight loss
NewAmsterdam Pharma Enrolls Over 9,000 Patients in Pivotal Phase 3 PREVAIL Global Cardiovascular Outcome Trial Evaluating the Effect of Obicetrapib in Patients with Established Atherosclerotic Cardiovascular Disease
NAMS
9 Apr 24
delighted to partner with the NewAmsterdam team to execute PREVAIL, a well-designed CVOT, and look forward to topline data on obicetrapib's MACE benefit
- Prev
- 1
- Next